‘Imitation Is Flattery,’ Regeneron Tells Amgen As It Prepares To Compete On Eylea
Amgen Seeing ‘Plenty Of Interest’; Supply Issues For Avastin Not A Factor For Eylea Yet
In the first earnings call since Amgen confirmed launch of the first US biosimilar to Regeneron’s near $6bn Eylea brand, the originator spoke of its confidence in defending its brand, while also touching on how supply issues for repackaged Avastin had impacted its operations.
